AI Article Synopsis
Article Abstract
A series of luminescent cyclometalated platinum(II) complexes of N^C^N ligands [N^C^N=2,6-bis(benzoxazol-2'-yl)benzene (bzoxb), 2,6-bis(benzothiazol-2'-yl)benzene (bzthb), and 2,6-bis(N-alkylnaphthoimidazol-2'-yl)benzene (naphimb)] has been synthesized and characterized. Two of the platinum(II) complexes have been structurally characterized by X-ray crystallography. Their electrochemical, electronic absorption, and luminescence properties have been investigated. In dichloromethane solution at room temperature, the cyclometalated N^C^N platinum(II) complexes exhibited rich luminescence with well-resolved vibronic-structured emission bands. The emission energies of the complexes are found to be closely related to the electronic properties of the N^C^N ligands. By varying the electronic properties of the cyclometalated ligands, a fine-tuning of the emission energies can be achieved, as supported by computational studies. Multilayer organic light-emitting devices have been prepared by utilizing two of these platinum(II) complexes as phosphorescent dopants, in which a saturated yellow emission with Commission International de I'Eclairage coordinates of (0.50, 0.49) was achieved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/chem.201301586 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
What happened to BBR3464 and where to from here for multinuclear platinum-based anticancer drugs?
Dalton Trans
December 2024
School of Natural Sciences, Faculty of Science and Engineering, Macquarie University, NSW, 2109, Australia.
The development of the trinuclear platinum(II) complex BBR3464 (also known as triplatin) in the late 1990s was meant to be a revolution in the field of platinum chemotherapy. What made it remarkable was that it defied many of the known structure-activity rules for platinums; it is cationic, has a single labile leaving group on each terminal platinum, and it binds DNA in ways different to mononuclear platinum drugs, like cisplatin and oxaliplatin. The flexible, long-range adducts the drug forms with DNA means that it showed activity in cancers not typically sensitive to platinums, and more importantly, BBR3464 demonstrated an ability to overcome acquired resistance to platinum drugs.
View Article and Find Full Text PDFA novel platinum(II) complex with a berberine derivative as a potential antitumor agent targeting G-quadruplex DNA.
Org Biomol Chem
December 2024
College of Marine Sciences, Beibu Gulf University, Qinzhou, China.
Article Synopsis
- - G-quadruplexes are important for cancer therapy, and understanding how compounds (ligands) interact with them is key for developing new anticancer drugs.
- - A new platinum(II) complex (Pt1) was created using a berberine derivative as a ligand, and its structure was studied using various scientific methods.
- - The study found that Pt1 binds well to G-quadruplex DNA, especially targeting the bcl-2 G-quadruplex, and showed effectiveness in inhibiting the growth of different tumor cells, indicating its potential as an antitumor agent.
Correction: Metallomesogens based on platinum(II) complexes: synthesis, luminescence and polarized emission.
Dalton Trans
December 2024
Institute of Polymer Optoelectronic Material and Devices, South China University of Technology, Guangzhou, 510640, China.
Article Synopsis
- The paper discusses the synthesis of metallomesogens, which are materials that combine metal complexes with liquid crystals, specifically focusing on platinum(II) complexes.
- It highlights the luminescent properties of these complexes, emphasizing how their unique structure affects their emission characteristics.
- The study also investigates the polarized emission of the metallomesogens, showcasing their potential applications in advanced materials and optoelectronics.
Site-Selective Ligand Functionalization Reverses Hypsochromic Luminescence Shifts in Platinum(II) Complexes of Benzannulated NCN-Coordinating Ligands.
Chemistry
December 2024
Department of Chemistry and the Manitoba Institute for Materials, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, R3T 2N2, Canada.
Ligands containing phenanthridine (benzo[c]quinoline) have presented notable exceptions to the conventional logic that increasing ligand benzannulation leads to bathochromic (red) shifts in the absorption and emission of their coordination complexes. The counterintuitive blue shifts have been attributed to the peculiar structure of phenanthridines, whose ground states are dominated by imine-bridged biphenyl resonance contributors. These serve to isolate the C=N unit electronically from the rest of the ligand framework and allow the C=N moiety to act as a 'shock-absorber', buffering against larger molecular distortions in a molecule's excited state, and reducing the observed pseudo-Stokes' shift.
View Article and Find Full Text PDFSynthesis of novel pyrimidine-based Schiff base complexes: Targeting Amyloid-β aggregation in Alzheimer's disease.
Bioorg Chem
November 2024
Department of Chemistry, Faculty of Science, Ege University, Bornova, Izmir 35100, Turkey. Electronic address:
Article Synopsis
- A novel Schiff base compound, 5-((3,3-diphenylalilidene)amino)pyrimidine-4-amine (L), was synthesized along with new platinum and ruthenium complexes, which were characterized through various analytical techniques.
- * The complexes demonstrated a strong ability to inhibit amyloid beta (Aβ) aggregation in human neuroblastoma cells (SH-SY5Y), significantly improving cell viability by up to 80% at 10 μM concentration compared to Aβ aggregation alone.
- * Further investigations using advanced microscopy and spectroscopy techniques confirmed that these metal complexes actively engage with Aβ and effectively inhibit its aggregation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!